Soru

Zorluk: Çok zorMonitoring and Treatment Evaluation

A 6161-year-old woman is brought to the emergency department by her husband due to progressive weakness and severe diarrhea. She has a history of metastatic melanoma and began combination immunotherapy with ipilimumab and nivolumab four weeks ago. Over the past three days, she has had up to eight large-volume, watery bowel movements daily, accompanied by diffuse abdominal cramping. Over the last 1212 hours, she has also developed new-onset palpitations, a sensation of a 'racing heart,' and mild shortness of breath at rest.

Her temperature is 37.8∘C37.8^\circ\text{C} (100.0∘F100.0^\circ\text{F}), blood pressure is 105/65 mmHg105/65\text{ mmHg}, pulse is 118/min118\text{/min} and irregular, and respiratory rate is 20/min20\text{/min}. Oxygen saturation is 96%96\% on room air. Physical examination reveals dry mucous membranes and diffuse, mild abdominal tenderness without guarding or rebound. Cardiovascular examination reveals an irregular rhythm with no murmurs, rubs, or gallops.

Which of the following are the most appropriate diagnostic and monitoring steps in the evaluation of this patient? (Select all that apply)

  1. Obtain a 12-lead electrocardiogram and measure serum cardiac biomarkers.Cevap
  2. Send stool samples for Clostridioides difficile toxin and a multiplex enteric pathogen panel.Cevap
  3. C
    Arrange for an urgent endomyocardial biopsy prior to performing non-invasive cardiac testing.
  4. D
    Diagnose medication-induced colitis clinically and bypass laboratory testing for infectious enteropathies.
  5. E
    Order a positron emission tomography scan of the abdomen to determine the anatomical extent of colonic inflammation.

Cevap

The correct evaluation steps are to obtain a 12-lead electrocardiogram with serum cardiac biomarkers and to send stool samples for infectious pathogen testing.
Immune checkpoint inhibitors, particularly combination therapies like ipilimumab and nivolumab, frequently cause immune-related adverse events. This patient exhibits classic signs of Grade 3 colitis (severe diarrhea) and possible myocarditis (arrhythmia, dyspnea). Because immune-mediated myocarditis has an exceptionally high mortality rate, immediate non-invasive cardiac evaluation with an electrocardiogram and cardiac biomarkers is mandatory. Concurrently, before initiating high-dose systemic corticosteroids to treat the presumed colitis, the clinician must definitively rule out infectious etiologies (e.g., Clostridioides difficile) via stool testing. Initiating profound immunosuppression in the setting of an active, undiagnosed infection represents a severe threat to patient safety.

Adım Adım Çözüm

1
Evaluate the clinical presentation of a patient currently on combination immunotherapy.
Identify symptoms consistent with two major potential immune-related adverse events: severe colitis (diarrhea) and myocarditis (palpitations, irregular pulse, dyspnea).
Combination immunotherapy (e.g., ipilimumab and nivolumab) carries a high risk of concurrent multi-organ toxicities.
2
Determine the diagnostic sequence for suspected immune-mediated myocarditis.
Select 12-lead electrocardiogram and serum troponin levels.
Myocarditis is a highly lethal complication requiring immediate, non-invasive baseline screening before considering invasive procedures like biopsy.
3
Determine the diagnostic sequence for suspected immune-mediated colitis.
Select stool testing for Clostridioides difficile and other enteric pathogens.
Infectious etiologies must be definitively ruled out before initiating the standard therapy for immune-mediated colitis (high-dose systemic corticosteroids), as administering steroids during an active, untreated gastrointestinal infection can lead to sepsis and death.

Anahtar Kavram

Monitoring and evaluation of immune checkpoint inhibitor toxicities requires recognizing concurrent multi-system involvement, prioritizing non-invasive cardiac testing, and ruling out infectious etiologies before administering systemic immunosuppression.
Bu soruyu puanla